Abiopharma

🔍 Lyon Joseph Douglas (Executive)

Company: CORCEPT THERAPEUTICS INC (CORT)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock at $13.56 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: false | shares_owned_after: 15,066.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,895 shares of Common Stock at $70.2386 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 10,171.00 | transaction_form_type: 4 | Footnotes: F2, F3, F1
• Sold 105 shares of Common Stock at $70.7571 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 10,066.00 | transaction_form_type: 4 | Footnotes: F2, F4, F1
• Acquired 200 shares of Common Stock at $71.38 per share (Direct)
  Date: 2025-09-02 | Code: A | equity_swap_involved: false | shares_owned_after: 10,266.00 | transaction_form_type: 4 | Footnotes: F5, F6, F1
• Acquired 200 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: A | equity_swap_involved: false | shares_owned_after: 10,466.00 | transaction_form_type: 4 | Footnotes: F7, F1
• Sold 189 shares of Common Stock at $71.38 per share (Direct)
  Date: 2025-09-03 | Code: F | equity_swap_involved: false | shares_owned_after: 10,277.00 | transaction_form_type: 4 | Footnotes: F8, F9, F1
• Sold 5,000 shares of Stock option (right to buy) at $13.56 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2030-02-07 | equity_swap_involved: false | shares_owned_after: 26,571.00 | transaction_form_type: 4 | Footnotes: F10

Footnotes:

• F1: Includes 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
• F2: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
• F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.74 to $70.77 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• F5: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.
• F6: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
• F7: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
• F8: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
• F9: The closing price on September 2, 2025 was used to calculate the withholding obligation.
• F10: Fully exercisable.
• REMARKS: Chief Accounting & Technology Officer